Cytrellis Biosystems named Jason Richey as its president and chief executive officer (CEO).
Cytrellis is a medical technology company dedicated to the development and commercialization of first-in-class aesthetic devices.
"We are thrilled to welcome Jason to the Cytrellis leadership team as he brings 25 years of proven experience in the medical device industry. As Cytrellis moves toward the nationwide launch of the ellacor System with Micro-Coring Technology in the United States, Jason's strength in commercial and operational functions will be invaluable," said John McDonough, chairman of the board of directors at Cytrellis.
Richey previously served as president and COO of Cutera, where he was responsible for making sure the company's vision, mission and corporate values were followed to meet or exceed the company's financial plans by implementing processes that drove improvements in global market share, top-line growth and gross margins.
He also served in a dual executive role as President of North America and President of the Neuromodulation Franchise for LivaNova, PLC, and Cyberonics where he served as the global vice president of sales, marketing and market access among many other roles.
"I'm honored to be joining Cytrellis at this pivotal stage of growth for the company," said Richey. "With our novel, disruptive technology and dedicated, talented team, I look forward to solidifying Cytrellis' place in the aesthetic device market as a leader in the industry."
